Puma Biotechnology Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van Puma Biotechnology zullen naar verwachting dalen met respectievelijk 4.1% en 45.4% per jaar, terwijl de winst per aandeel naar verwachting zal dalen met 43.8% per jaar.

Belangrijke informatie

-45.4%

Groei van de winst

-43.8%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	-4.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	20 Nov 2024

Recente toekomstige groei-updates

Recent updates

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Nov 14

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Sep 07

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Aug 15

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Sep 05

Winst- en omzetgroeiprognoses

NasdaqGS:PBYI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	227	20	50	60	2
12/31/2025	221	20	58	46	2
12/31/2024	224	15	51	39	2
9/30/2024	244	23	34	34	N/A
6/30/2024	219	9	33	33	N/A
3/31/2024	227	15	35	36	N/A
12/31/2023	236	22	14	27	N/A
9/30/2023	229	4	5	24	N/A
6/30/2023	230	-2	11	31	N/A
3/31/2023	235	5	-6	14	N/A
12/31/2022	228	0	-23	-16	N/A
9/30/2022	218	10	-29	-29	N/A
6/30/2022	207	-34	-36	-36	N/A
3/31/2022	201	-49	-22	-22	N/A
12/31/2021	253	-29	21	21	N/A
9/30/2021	250	-48	20	20	N/A
6/30/2021	255	-35	12	12	N/A
3/31/2021	272	-27	18	28	N/A
12/31/2020	225	-60	-9	1	N/A
9/30/2020	235	-56	-2	8	N/A
6/30/2020	241	-42	-11	-1	N/A
3/31/2020	224	-82	27	27	N/A
12/31/2019	272	-76	22	22	N/A
9/30/2019	280	-95	28	28	N/A
6/30/2019	287	-92	28	28	N/A
3/31/2019	284	-99	-35	-34	N/A
12/31/2018	251	-114	-25	-24	N/A
9/30/2018	202	-147	-117	-67	N/A
6/30/2018	145	-210	N/A	-114	N/A
3/31/2018	94	-243	N/A	-143	N/A
12/31/2017	28	-292	N/A	-172	N/A
9/30/2017	6	-301	N/A	-178	N/A
6/30/2017	N/A	-289	N/A	-158	N/A
3/31/2017	N/A	-278	N/A	-143	N/A
12/31/2016	N/A	-276	N/A	-142	N/A
9/30/2016	N/A	-265	N/A	-134	N/A
6/30/2016	N/A	-260	N/A	-136	N/A
3/31/2016	N/A	-258	N/A	-139	N/A
12/31/2015	N/A	-239	N/A	-154	N/A
9/30/2015	N/A	-225	N/A	-140	N/A
6/30/2015	N/A	-200	N/A	-127	N/A
3/31/2015	N/A	-175	N/A	-110	N/A
12/31/2014	N/A	-142	N/A	-77	N/A
9/30/2014	N/A	-110	N/A	-72	N/A
6/30/2014	N/A	-89	N/A	-60	N/A
3/31/2014	N/A	-63	N/A	-54	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van PBYI zal naar verwachting de komende 3 jaar dalen ( -45.4% per jaar).

Winst versus markt: De winst van PBYI zal naar verwachting de komende 3 jaar dalen ( -45.4% per jaar).

Hoge groeiwinsten: De winst van PBYI zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van PBYI zal naar verwachting de komende 3 jaar dalen ( -4.1% per jaar).

Hoge groei-inkomsten: De omzet van PBYI zal naar verwachting de komende 3 jaar dalen ( -4.1% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PBYI naar verwachting over 3 jaar hoog zal zijn

Puma Biotechnology Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates increase by 16%

Puma Biotechnology, Inc. Revises Earnings Guidance for the Full Year 2024

Puma Biotechnology, Inc. Provides Earning Guidance for the Third Quarter and Full Year of 2024

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Consensus EPS estimates increase by 45%, revenue downgraded

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Recent updates

Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Investor sentiment deteriorates as stock falls 16%

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Consensus EPS estimates increase by 16%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. Revises Earnings Guidance for the Full Year 2024

Puma Biotechnology, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Independent Director recently sold US$81k worth of stock

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Investor sentiment deteriorates as stock falls 27%

Independent Director notifies of intention to sell stock

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Puma Biotechnology, Inc. Provides Earning Guidance for the Third Quarter and Full Year of 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Founder recently sold US$81k worth of stock

Founder notifies of intention to sell stock

Puma Biotechnology, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Investor sentiment improves as stock rises 22%

Founder notifies of intention to sell stock

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)

Investor sentiment deteriorates as stock falls 20%

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Puma Biotechnology, Inc., Annual General Meeting, Jun 18, 2024

Puma Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Investor sentiment deteriorates as stock falls 15%

Consensus EPS estimates increase by 45%, revenue downgraded

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Puma Biotechnology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Founder notifies of intention to sell stock

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Investor sentiment improves as stock rises 15%

Independent Director recently sold US$71k worth of stock

Independent Director notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Puma Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

New major risk - Revenue and earnings growth

Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Puma Biotechnology, Inc. Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel Versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 32%, revenue downgraded

Investor sentiment improves as stock rises 17%

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations